Dr Reddy’s Laboratories Ltd has launched Sevelamer Carbonate tablets, 800 mg, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) tablets, in the US market following approval by the US Food and Drug Administration (USFDA).
A release issued by the drug maker last night citing IMSE Health said Renvela brand and generic had US sales of approximately USD 1.88 billion (moving annual turnover) for the most recent twelve months ending in July 2017. “We are very pleased to bring Sevelamer Carbonate tablets to market at this time. This launch represents Dr Reddy’s expertise and commitment to provide affordable alternatives for complex, limited-competition products to market,” Alok Sonig, Executive Vice President and Head of the North America Generics business DRL said.
This is the company’s eighth overall and fourth limited-competition launch this fiscal year, he added. Dr Reddy’s Sevelamer Carbonate tablets, 800 mg are available in the bottle count size of 270 tablets. Renvela is a trademark of Genzyme Corporation, it further said.